- Home
- BW vs PRLD Comparison
BW vs PRLD Comparison
Compare BW & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BW
- PRLD
- Stock Information
- Founded
- BW 1867
- PRLD 2016
- Country
- BW United States
- PRLD United States
- Employees
- BW N/A
- PRLD N/A
- Industry
- BW Building Products
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- BW Industrials
- PRLD Health Care
- Exchange
- BW Nasdaq
- PRLD Nasdaq
- Market Cap
- BW 45.3M
- PRLD 50.1M
- IPO Year
- BW N/A
- PRLD 2020
- Fundamental
- Price
- BW $0.84
- PRLD $0.94
- Analyst Decision
- BW Buy
- PRLD Strong Buy
- Analyst Count
- BW 2
- PRLD 2
- Target Price
- BW $3.50
- PRLD $4.50
- AVG Volume (30 Days)
- BW 1.8M
- PRLD 138.2K
- Earning Date
- BW 05-12-2025
- PRLD 05-06-2025
- Dividend Yield
- BW N/A
- PRLD N/A
- EPS Growth
- BW N/A
- PRLD N/A
- EPS
- BW N/A
- PRLD N/A
- Revenue
- BW $734,239,000.00
- PRLD $7,000,000.00
- Revenue This Year
- BW $9.70
- PRLD N/A
- Revenue Next Year
- BW $10.16
- PRLD N/A
- P/E Ratio
- BW N/A
- PRLD N/A
- Revenue Growth
- BW 12.90
- PRLD N/A
- 52 Week Low
- BW $0.22
- PRLD $0.61
- 52 Week High
- BW $2.99
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- BW 61.11
- PRLD 55.15
- Support Level
- BW $0.68
- PRLD $0.86
- Resistance Level
- BW $0.79
- PRLD $1.00
- Average True Range (ATR)
- BW 0.10
- PRLD 0.10
- MACD
- BW 0.00
- PRLD -0.00
- Stochastic Oscillator
- BW 59.41
- PRLD 58.89
About BW Babcock & Wilcox Enterprises Inc.
Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.